Exhibit (a)(1)(J)

         [LETTERHEAD OF MILBERG WEISS BERSHAD HYNES & LERACH LLP]


                                May 31, 2000

                                                        VIA FACSIMILE
                                                        -------------

Board of Directors of Shopke
Board of Directors of ProVantage
c/o Nancy Senate
FOLEY & LARDNER
150 East Gilman Street
Madison, WI 53701-1497

Board of Directors of Merck
c/o Gary P. Cooperstein
FRIED, FRANK, HARRIS,
  SHRIVER & JACOBSON
One New York Plaza
New York, NY 10004

     Re:   ProVantage Shareholder Litigation

Dear Board Members:

     The  Tender  Offer  Documents  issued in  connection  with the sale of
ProVantage,  Inc., including the SEC forms 14D-1 and 14-9 ("Documents") are
false and  misleading  in that they fail to disclose  material  information
rendering such documents false and misleading.

     The Documents conceal material information relating to the motivations
and benefits which will be obtained by the Board Members of ProVantage  and
Shopko upon  consummation of the  transaction.  For example,  the Documents
fail  to  disclose  the  fact  that  Shopko's  61%  ownership  interest  in
ProVantage  is highly  illiquid.  Though  Shopko's  ownership  stake was no
longer  subject to the Rule 144 time  restrictions,  it was  subject to the
Rule 144 volume  restrictions  which,  as a practical  matter,  effectively
precluded it from selling its interest in ProVantage  for years at anywhere
near the price obtained in this transaction.  Unlike Shopko, our client and
the other public  stockholders of ProVantage were not so  disadvantaged  as
they have never faced the illiquidity issues faced by Shopko.

     The Documents also conceal the benefits that will be reaped by Girard,
Kramer,  Wolf and Podany upon consummation of the Tender Offer by virtue of
their  relationship with Shopko.  Furthermore,  the Documents  conveniently
omit from the "Background" section that on February 29, 2000, one day after
Merck  submitted  an offer to  purchase  the  company,  ProVantage  granted
options  to  key  officers  which  have  a  post-exercise  price  value  of
$1,450,000.

     The Documents are fraught with material  omissions and  misstatements.
Merck must  refrain from  purchasing  ProVantage  shares from  ProVantage's
shareholders in the Tender Offer until it makes adequate  disclosure of all
material information to ProVantage shareholders.  Plaintiffs' concerns with
the  Tender  Offer  documents  are  many and  given  the  defects  in these
materials,  our  client  immediately  attempted  to contact  Nancy  Senate,
Shopko's  and  ProVantage's  counsel,  to apprise her of the  necessity  of
correcting  these problems and/or  refraining from  consummating the Tender
Offer,  as  proposed.  She  has not  responded.  We view  these  issues  as
extremely important.

     The Tender Offer is scheduled to close on June 14, 2000.  Accordingly,
the necessary corrections must be provided to ProVantage shareholders on or
before June 5, 2000. If we do not hear from you on or before Thursday, June
1,  2000,  we  will  arrange  to  take  the  necessary   steps  to  protect
ProVantage's public stockholders.

                                        Very truly yours,

                                        /s/ Randall H. Steinmeyer

                                        RANDALL H. STEINMEYER

RHS:krj